Literature DB >> 21242893

Hematopoietic stem/precursor cells as HIV reservoirs.

Lucy A McNamara1, Kathleen L Collins.   

Abstract

PURPOSE OF REVIEW: Although latent HIV-1 infection in CD4+ T cells contributes to HIV persistence, there is mounting evidence that other viral reservoirs exist. Here, we review recent data suggesting that the infection of hematopoietic progenitor cells creates additional reservoirs for HIV in vivo. RECENT
FINDINGS: New studies suggest that some types of hematopoietic progenitor cells have the potential to generate reservoirs for HIV. This review focuses on two types that can be infected by HIV in vitro and in vivo: multipotent hematopoietic progenitor cells in the bone marrow and circulating mast cell progenitors. Of these two types, only CD34+ bone marrow cells have been shown to harbor latent provirus in HIV-positive individuals with undetectable viral loads on highly active antiretroviral therapy (HAART). Latent infection of these long-lived cell types may create a significant barrier to HIV eradication; the infection of hematopoietic stem cells in particular could lead to an HIV reservoir that does not appreciably decay over the lifespan of the host.
SUMMARY: To eradicate HIV infection, it will be necessary to purge all viral reservoirs in the host. The findings highlighted here suggest that multipotent hematopoietic progenitor cells and possibly tissue mast cells may constitute significant reservoirs for HIV that must be addressed in order to eliminate HIV infection. Future studies are needed to determine which types of CD34+ cells are infected in vivo and whether infected CD34+ cells contribute to residual viremia in people with undetectable viral loads on HAART.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242893      PMCID: PMC3045752          DOI: 10.1097/COH.0b013e32834086b3

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  51 in total

1.  Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells.

Authors:  Janet D Siliciano; Joleen Kajdas; Diana Finzi; Thomas C Quinn; Karen Chadwick; Joseph B Margolick; Colin Kovacs; Stephen J Gange; Robert F Siliciano
Journal:  Nat Med       Date:  2003-05-18       Impact factor: 53.440

2.  HIV rebounds from latently infected cells, rather than from continuing low-level replication.

Authors:  Beda Joos; Marek Fischer; Herbert Kuster; Satish K Pillai; Joseph K Wong; Jürg Böni; Bernard Hirschel; Rainer Weber; Alexandra Trkola; Huldrych F Günthard
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-20       Impact factor: 11.205

Review 3.  The influence of human immunodeficiency virus-1 on hematopoiesis.

Authors:  A Moses; J Nelson; G C Bagby
Journal:  Blood       Date:  1998-03-01       Impact factor: 22.113

4.  The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy.

Authors:  B Ramratnam; J E Mittler; L Zhang; D Boden; A Hurley; F Fang; C A Macken; A S Perelson; M Markowitz; D D Ho
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

5.  Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow.

Authors:  T M Folks; S W Kessler; J M Orenstein; J S Justement; E S Jaffe; A S Fauci
Journal:  Science       Date:  1988-11-11       Impact factor: 47.728

6.  Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy.

Authors:  T W Chun; L Stuyver; S B Mizell; L A Ehler; J A Mican; M Baseler; A L Lloyd; M A Nowak; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

7.  Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults.

Authors:  K S Slobod; T A Bennett; P J Freiden; A M Kechli; N Howlett; P M Flynn; D R Head; D K Srivastava; J M Boyett; M K Brenner; J V Garcia
Journal:  Blood       Date:  1996-11-01       Impact factor: 22.113

Review 8.  Mast cell growth, differentiation, and death.

Authors:  Michael F Gurish; Joshua A Boyce
Journal:  Clin Rev Allergy Immunol       Date:  2002-04       Impact factor: 8.667

9.  CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1.

Authors:  T F Neal; H K Holland; C M Baum; F Villinger; A A Ansari; R Saral; J R Wingard; W H Fleming
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  IgE-FcepsilonRI interactions determine HIV coreceptor usage and susceptibility to infection during ontogeny of mast cells.

Authors:  J Bruce Sundstrom; Gregory A Hair; Aftab A Ansari; W Evan Secor; Alasdair M Gilfillan; Dean D Metcalfe; Arnold S Kirshenbaum
Journal:  J Immunol       Date:  2009-05-15       Impact factor: 5.422

View more
  32 in total

1.  Short communication: Colony-forming hematopoietic progenitor cells are not preferentially infected by HIV type 1 subtypes A and D in vivo.

Authors:  Caroline E Mullis; Amy E Oliver; Leigh Anne Eller; David Guwatudde; Amy C Mueller; Michael A Eller; Hannah Kibuuka; Merlin Robb; Thomas C Quinn; Andrew D Redd
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-02       Impact factor: 2.205

2.  HIV-1 DNA is detected in bone marrow populations containing CD4+ T cells but is not found in purified CD34+ hematopoietic progenitor cells in most patients on antiretroviral therapy.

Authors:  Christine M Durand; Gabriel Ghiaur; Janet D Siliciano; S Alireza Rabi; Evelyn E Eisele; Maria Salgado; Liang Shan; Jun F Lai; Hao Zhang; Joseph Margolick; Richard J Jones; Joel E Gallant; Richard F Ambinder; Robert F Siliciano
Journal:  J Infect Dis       Date:  2012-01-24       Impact factor: 5.226

3.  Hematopoietic cell transplantation and HIV cure: where we are and what next?

Authors:  Shimian Zou; Simone Glynn; Daniel Kuritzkes; Monica Shah; Nakela Cook; Nancy Berliner
Journal:  Blood       Date:  2013-09-05       Impact factor: 22.113

Review 4.  Current Strategies for Elimination of HIV-1 Latent Reservoirs Using Chemical Compounds Targeting Host and Viral Factors.

Authors:  Maxime J Jean; Guillaume Fiches; Tsuyoshi Hayashi; Jian Zhu
Journal:  AIDS Res Hum Retroviruses       Date:  2018-12-12       Impact factor: 2.205

Review 5.  Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis.

Authors:  Anupam Banerjee; Marianne Strazza; Brian Wigdahl; Vanessa Pirrone; Olimpia Meucci; Michael R Nonnemacher
Journal:  J Neurovirol       Date:  2011-07-07       Impact factor: 2.643

Review 6.  Substance abuse, HIV-1 and hepatitis.

Authors:  Nirzari Parikh; Michael R Nonnemacher; Vanessa Pirrone; Timothy Block; Anand Mehta; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2012-10       Impact factor: 1.581

7.  Efficiency of bridging-sheet recruitment explains HIV-1 R5 envelope glycoprotein sensitivity to soluble CD4 and macrophage tropism.

Authors:  Olivia O'Connell; Alexander Repik; Jacqueline D Reeves; Maria Paz Gonzalez-Perez; Briana Quitadamo; Elizabeth D Anton; Maria Duenas-Decamp; Paul Peters; Rongheng Lin; Susan Zolla-Pazner; Davide Corti; Aaron Wallace; Shixia Wang; Xiang-Peng Kong; Shan Lu; Paul R Clapham
Journal:  J Virol       Date:  2012-10-10       Impact factor: 5.103

8.  Hematopoietic stem cells and HIV infection.

Authors:  Matthew Pace; Una O'Doherty
Journal:  J Infect Dis       Date:  2013-04-03       Impact factor: 5.226

Review 9.  Neutropenia during HIV infection: adverse consequences and remedies.

Authors:  Xin Shi; Matthew D Sims; Michel M Hanna; Ming Xie; Peter G Gulick; Yong-Hui Zheng; Marc D Basson; Ping Zhang
Journal:  Int Rev Immunol       Date:  2014-03-21       Impact factor: 5.311

10.  Humanized mouse model of mast cell-mediated passive cutaneous anaphylaxis and passive systemic anaphylaxis.

Authors:  Paul J Bryce; Rustom Falahati; Laurie L Kenney; John Leung; Christopher Bebbington; Nenad Tomasevic; Rebecca A Krier; Chia-Lin Hsu; Leonard D Shultz; Dale L Greiner; Michael A Brehm
Journal:  J Allergy Clin Immunol       Date:  2016-04-06       Impact factor: 10.793

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.